(Sharecast News) - Johnson & Johnson confirmed on Monday that it has agreed to buy biopharmaceutical firm Intra-Cellular Therapies for around $14.6bn.
Inter-Cellular is focused on the development and commercialisation of therapeutics for central nervous system (CNS) disorders.

Under the terms of the deal, J&J will pay $132.00 per share...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE